Translational Research in Cancer Genomic Medicine

癌症基因组医学转化研究

基本信息

批准号：
8127865
负责人：
Wen-Hwa Lee
金额：
$ 30.41万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-24 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8127865
关键词：
Medicine Translational Research cancer genomics

项目摘要

DESCRIPTION (provided by applicant): Support is requested to initiate a comprehensive training program in Translational Research in Cancer Genomic Medicine (TRCGM) at the University of California, Irvine. Intensive biomedical research efforts have yielded significant advances in clinical outcomes for a subset of cancers. However, developing useful and effective drugs for treating cancer remains a great challenge. Over the last several years, because of the completion of the human genome, the improved understanding of network connections in cellular regulatory pathways and advance in chemical biology, a plethora of new potential drug targets has been identified through the persistent work in many academic research institutions. These drug targets hold the promise of eventually resulting in the next generation of anti-cancer drugs. UCI has strong programs in basic and clinical cancer research, chemical biology, the development and use of animal models for cancer research. However, until now, no strategy has combined and leveraged these strengths of academic centers in order to train researchers who will be able to integrate basic science with all the aspects of drug development. The 18 proposed faculty were selected as the program faculty for the TRCGM because their research has an important translational component and all are interested in training future translational fellows. The program will focus on training graduate students and postdoctoral and medical fellows in cancer research areas that are highly related to translational research including target identification, chemical biology, preclinical animal models, and clinical trials. Trainees in this program will develop a thorough understanding of the steps required to translate laboratory findings into drugs that may significantly benefit patients in a clinical setting. The NIH has recognized the need for such training in its Roadmap Initiatives. The TRCGM will meet these needs and will train a new cadre of cancer researchers who are able to rapidly and effectively translate laboratory research into medicine, which will improve clinical outcomes by reducing cancer morbidity and mortality.

描述（由申请人提供）：请求支持在加州大学欧文分校启动癌症基因组医学转化研究（TRCGM）综合培训计划。深入的生物医学研究工作在部分癌症的临床结果方面取得了重大进展。然而，开发有用且有效的治疗癌症的药物仍然是一个巨大的挑战。在过去的几年里，由于人类基因组的完成、对细胞调控途径网络连接的了解的加深以及化学生物学的进步，通过许多学术研究机构的不懈努力，已经发现了大量新的潜在药物靶点。。这些药物靶标有望最终产生下一代抗癌药物。 UCI 在基础和临床癌症研究、化学生物学、癌症研究动物模型的开发和使用方面拥有强大的项目。然而，到目前为止，还没有任何策略能够结合和利用学术中心的这些优势来培训能够将基础科学与药物开发的各个方面相结合的研究人员。 18 名拟议的教师被选为 TRCGM 的项目教师，因为他们的研究具有重要的转化成分，并且所有人都对培训未来的转化研究员感兴趣。该项目将重点培养与转化研究高度相关的癌症研究领域的研究生、博士后和医学研究员，包括靶标识别、化学生物学、临床前动物模型和临床试验。该计划的学员将全面了解将实验室发现转化为可能在临床环境中显着造福患者的药物所需的步骤。美国国立卫生研究院 (NIH) 已在其路线图计划中认识到此类培训的必要性。 TRCGM 将满足这些需求，并将培训一支新的癌症研究人员队伍，他们能够快速有效地将实验室研究转化为医学，从而通过降低癌症发病率和死亡率来改善临床结果。